196 related articles for article (PubMed ID: 35628603)
21. Expression of PKG2 in ovarian cancer and its effect on epidermal growth factor receptor.
Xu H; Zhang Z; Li P; Lu X; Chen B; Lan T
J BUON; 2020; 25(2):729-735. PubMed ID: 32521860
[TBL] [Abstract][Full Text] [Related]
22. Reduced syndecan-1 expression stimulates heparin-binding growth factor-mediated invasion in ovarian cancer cells in a urokinase-independent mechanism.
Matsuzaki H; Kobayashi H; Yagyu T; Wakahara K; Kondo T; Kurita N; Sekino H; Inagaki K; Suzuki M; Kanayama N; Terao T
Oncol Rep; 2005 Aug; 14(2):449-57. PubMed ID: 16012729
[TBL] [Abstract][Full Text] [Related]
23. Chromatin target of protein arginine methyltransferase regulates invasion, chemoresistance, and stemness in epithelial ovarian cancer.
Feng X; Li L; Wang L; Luo S; Bai X
Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30910850
[TBL] [Abstract][Full Text] [Related]
24. Expression of the cell-surface heparan sulfate proteoglycan mRNA in monkey submandibular gland.
Yamagata E; Kamada A
J Osaka Dent Univ; 1999 Oct; 33(2):83-7. PubMed ID: 10863479
[TBL] [Abstract][Full Text] [Related]
25. Potential role of the HOXD8 transcription factor in cisplatin resistance and tumour metastasis in advanced epithelial ovarian cancer.
Sun P; Song Y; Liu D; Liu G; Mao X; Dong B; Braicu EI; Sehouli J
Sci Rep; 2018 Sep; 8(1):13483. PubMed ID: 30194340
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells.
Lee C
Mol Med Rep; 2015 Jul; 12(1):1485-92. PubMed ID: 25815442
[TBL] [Abstract][Full Text] [Related]
27. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
28. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
Wu D; Lu P; Mi X; Miao J
Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of Hec1 expression enhances the sensitivity of human ovarian cancer cells to paclitaxel.
Mo QQ; Chen PB; Jin X; Chen Q; Tang L; Wang BB; Li KZ; Wu P; Fang Y; Wang SX; Zhou JF; Ma D; Chen G
Acta Pharmacol Sin; 2013 Apr; 34(4):541-8. PubMed ID: 23474708
[TBL] [Abstract][Full Text] [Related]
30. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
31. Gli affects the stemness and prognosis of epithelial ovarian cancer via homeobox protein NANOG.
Zhao H; Li N; Pang Y; Zhao J; Wu X
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33313950
[TBL] [Abstract][Full Text] [Related]
32. SiRNA-Mediated
Xue T; Wang L; Li Y; Song H; Chu H; Yang H; Guo A; Jiao J
Int J Med Sci; 2019; 16(11):1510-1516. PubMed ID: 31673243
[No Abstract] [Full Text] [Related]
33. PDCD1 strengthens the sensitivity of ovarian cancer to cisplatin chemotherapy by promoting apoptosis.
Li Q; Gao JF; Qi BL
J BUON; 2017; 22(3):746-756. PubMed ID: 28730785
[TBL] [Abstract][Full Text] [Related]
34. [Biological effect of down-regulating of MTRR gene on cisplatin-resistant ovarian cancer SKOV3 cells in vitro and in vivo studies].
Chen J; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Feb; 51(2):126-34. PubMed ID: 26917482
[TBL] [Abstract][Full Text] [Related]
35. Differential expression of cell surface heparan sulfate proteoglycans in human mammary epithelial cells and lung fibroblasts.
Lories V; Cassiman JJ; Van den Berghe H; David G
J Biol Chem; 1992 Jan; 267(2):1116-22. PubMed ID: 1339431
[TBL] [Abstract][Full Text] [Related]
36. Post-transcriptional regulation of syndecan-1 expression by cAMP in peritoneal macrophages.
Yeaman C; Rapraeger AC
J Cell Biol; 1993 Aug; 122(4):941-50. PubMed ID: 8394371
[TBL] [Abstract][Full Text] [Related]
37. ERp57‑small interfering RNA silencing can enhance the sensitivity of drug‑resistant human ovarian cancer cells to paclitaxel.
Li S; Zhao X; Chang S; Li Y; Guo M; Guan Y
Int J Oncol; 2019 Jan; 54(1):249-260. PubMed ID: 30431082
[TBL] [Abstract][Full Text] [Related]
38. Role of Syndecans in Ovarian Cancer: New Diagnostic and Prognostic Biomarkers and Potential Therapeutic Targets.
Oto J; Le QK; Schäfer SD; Kiesel L; Marí-Alexandre J; Gilabert-Estellés J; Medina P; Götte M
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370735
[TBL] [Abstract][Full Text] [Related]
39. Knockdown of Hypoxia-Inducible Factor 1α (HIF-1α) Promotes Autophagy and Inhibits Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Ovarian Cancer Cells.
Huang J; Gao L; Li B; Liu C; Hong S; Min J; Hong L
Med Sci Monit; 2019 Jun; 25():4250-4263. PubMed ID: 31175269
[TBL] [Abstract][Full Text] [Related]
40. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
